EU Agrees on Critical Medicines Act to Boost Domestic Production
The European Union has reached a provisional agreement on the Critical Medicines Act, a legislative measure designed to reduce dependence on pharmaceutical imports from Asia and prevent drug shortages. The law incentivizes domestic production of essential medicines like antibiotics and insulin by reforming public procurement rules to prioritize supply security over lowest price. It also facilitates joint purchasing among member states and establishes frameworks for emergency stock sharing. This strategic move aims to strengthen the EU’s healthcare resilience and pharmaceutical autonomy following vulnerabilities exposed during the pandemic.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
Cyprus Minister Praises EU Deal to Secure Critical Medicine Supplies
Cyprus Health Minister Neophytos Charalambides has welcomed a provisional agreement between the Council of the European Union and the European Parliament on new regulations designed to secure the supply of critical medicines across the bloc. The deal aims to prevent shortages of essential drugs, such as antibiotics, by reducing vulnerabilities and diversifying supply chains. Key measures include incentivizing EU-based manufacturing of medicines and active ingredients to decrease dependency on third countries, and introducing resilience requirements in public procurement procedures. The agreement also facilitates joint procurement among member states, lowering the minimum number of states required for Commission-led procurement from nine to five, thereby strengthening collective leverage. Furthermore, it establishes transparent contingency stock requirements based on solidarity and proportionality. This legislation creates the first comprehensive framework to address medicine shortages in the EU. European Parliament President Roberta Metsola also praised the deal, highlighting Cyprus's cooperation. The rules will enter into force following formal approval by both legislative bodies, marking a significant step toward enhancing Europe's health security and pharmaceutical autonomy.
Cyprus MailEU Approves Critical Medicines Act to Boost Domestic Drug Production
Negotiators from the European Parliament and EU member states have approved the final version of the Critical Medicines Act, aiming to resolve recurring shortages of essential drugs like antibiotics and painkillers. This legislation responds to fragile supply chains caused by the relocation of pharmaceutical production to Asia in recent decades. The new law shifts public procurement criteria away from solely prioritizing the lowest price, allowing member states to consider supply security and European manufacturing locations. It mandates that 50 percent of active ingredients for critical medicines must originate within the EU. Additionally, the act facilitates faster approval and funding for strategic research and production projects, while encouraging joint procurement among member states. Although a proposal for redistributing stock between states was removed, the agreement improves transparency regarding stock levels across Europe. Officials describe this as a fundamental change in medicine procurement, addressing structural causes of shortages rather than just symptoms. Final formal consent from the Parliament and member states is expected before the summer break, marking a significant step toward strengthening the EU's pharmaceutical independence and ensuring patient access to vital treatments.
Aktuell - FAZ.NETEU Reaches Provisional Deal on Critical Medicines Act to Boost Supply Security
The European Union has reached a provisional agreement on the Critical Medicines Act, aimed at reducing medicine shortages and strengthening supply chain resilience. Finalized between the Council presidency and the European Parliament on May 12, the legislation requires formal approval before entering into force. The act targets essential medicines like antibiotics and insulin, addressing vulnerabilities exposed by the pandemic and global disruptions. Key measures include facilitating joint procurement among member states by lowering the threshold for Commission-led purchases from nine to five countries. It also supports strategic domestic production projects through faster administrative processes and funding access, while allowing public buyers to prioritize supply security over lowest price. The agreement seeks to balance affordability with industrial resilience, avoiding full self-sufficiency but reducing dependence on single external suppliers. The European Medicines Agency welcomed the deal, noting it complements existing monitoring tools. This legislation is part of a broader pharmaceutical agenda to ensure better access to treatments and enhance emergency preparedness across the bloc, particularly benefiting smaller member states with limited market attractiveness.
https://eutoday.netNew EU Pharmaceutical Law Targets Supply Chain Dependencies on India and China
The European Union has agreed on the Critical Medicines Act, a new legislative framework designed to reduce reliance on pharmaceutical imports from India and China. This move addresses significant shortages of essential medicines experienced during the Covid-19 pandemic, shifting the strategic focus from securing the lowest possible prices to ensuring a secure and resilient supply of medications. The legislation aims to diversify supply chains and strengthen Europe's domestic production capabilities for critical medicines and their active ingredients. A key component involves reforming public procurement rules, which previously favored cheap imports through 'winner-takes-all' tenders. These negotiations were notably contentious, lasting over four hours among EU lawmakers. The act also serves as a countermeasure to similar efforts by the United States to expand its own pharmaceutical manufacturing base. Officials, including Cypriot Health Minister Neophytos Charalambides and European Parliament negotiator Tomislav Sokol, emphasized the importance of keeping industry within Europe to prevent future vulnerabilities and ensure patient access to vital drugs like antibiotics without disruption.
POLITICOEU Reaches Agreement on Critical Medicines Law to Secure Drug Supplies
The European Union Council and the European Parliament have reached a provisional agreement on the Critical Medicines Law, aimed at bolstering the resilience of the EU healthcare sector. This legislation seeks to prevent shortages of essential medicines, including antibiotics, insulin, and painkillers, by diversifying supply chains and reducing dependence on non-EU suppliers such as China and India. Key measures include strengthening domestic production capacity for critical drugs and their active substances, mandating durability-oriented conditions in public procurements, and providing flexibility for an 'EU preference' approach. The law also facilitates joint purchasing mechanisms, allowing the European Commission to execute joint buys upon the request of five member states, thereby increasing collective bargaining power. Additionally, it establishes frameworks for sharing emergency stock data and voluntarily redistributing medicines among member states during crises. This move addresses long-standing vulnerabilities where generic drug production has largely occurred outside Europe, ensuring greater supply security and accessibility for citizens across the Union.
Anadolu Ajansı Güncel HaberlerEU Enacts New Law to Boost Domestic Medicine Production and Reduce Reliance on Asia
The European Union has agreed on the Critical Medicines Act, a legislative measure designed to reduce dependence on pharmaceutical imports from India and China. This initiative aims to address critical drug shortages experienced during the pandemic by incentivizing drug manufacturers to produce medicines and active ingredients within Europe. Key strategies include providing state aid and introducing procurement perks that favor local production over the lowest-cost bids, which previously drove manufacturing overseas. The agreement follows intense negotiations, particularly regarding controversial changes to public procurement rules. EU officials, including Cyprus Health Minister Neophytos Charalambides and MEP Tomislav Sokol, emphasized the importance of securing supply chains and ensuring patient access to essential drugs like antibiotics. The act also serves as a strategic counter to similar manufacturing boost efforts in the United States. By diversifying supply chains and strengthening domestic capacity, the EU seeks to mitigate vulnerabilities associated with foreign manufacturing hold-ups and ensure long-term health security for its citizens.
POLITICOEMA Welcomes Political Agreement on Critical Medicines Act
The European Medicines Agency (EMA) has welcomed the provisional political agreement reached between the European Parliament and the Council of the European Union on the proposed Critical Medicines Act (CMA). The EMA emphasizes that at a time of increasing global disruptions, resilient and secure supply chains for critical medicines are essential to protect public health across the EU. The agreement comes in response to serious medicine shortages faced by EU Member States in recent years, exacerbated by global challenges such as the COVID-19 pandemic and geopolitical tensions. The CMA aims to strengthen the security of supply for critical medicines, reducing dependency on non-EU sources and improving crisis preparedness within the bloc.
News and press releases